This domain may be for sale!
This domain may be for sale!
Pfizer unveils positive phase 3 trial results for RSV vaccinePfizer (PFE) has released the results from its Phase 3 clinical trial for its RSV vaccine. The trial showed positive outcomes for adults aged 18-59, widening the population that can potentially benefit from the vaccine. Previously, Pfizer's RSV vaccine had been approved for use in pregnant women and adults aged 60 and older. Yahoo Financ
リリース、障害情報などのサービスのお知らせ
最新の人気エントリーの配信
処理を実行中です
j次のブックマーク
k前のブックマーク
lあとで読む
eコメント一覧を開く
oページを開く